舒尼替尼治疗晚期难治性乳腺癌癌性溃疡的临床观察

Clinical observation of sunitinib treatment for refractory advanced breast cancer ulcer

目的初步观察舒尼替尼对晚期难治性乳腺癌癌性溃疡的临床疗效及不良反应。方法2008年12月至2010年5月，入住解放军第三。七医院乳腺肿瘤科的乳腺癌癌性溃疡患者9例，接受单药舒尼替尼的治疗，用药方案根据不良反应进行调整，通过测量比较癌性溃疡变化，进行临床疗效评价。结果共9例乳腺癌癌性溃疡患者接受了舒尼替尼治疗。临床客观有效3例，达到肿瘤临床控制7例。舒尼替尼主要不良反应包括皮肤黄染、乏力、手足综合征、中性粒细胞减少、血小板减少及高血压等。结论舒尼替尼对乳腺癌癌性溃疡有突出的疗效，中性粒细胞减少、血小板减少和高血压为其主要剂量限制性毒性。

Objective To observe the preliminary efficacies and adverse events of sunitinib in the treatment of metastatic breast cancer ulcer. Methods From December 2008 to May 2010, patients with advanced breast cancer ulcer took a single sunitinib. The dosage was adjusted on the basis of adverse events. And clinical response was evaluated. Results Nine patients with advanced breast cancer ulcer finished the treatment. The objective response and the clinical benefit time to progression of sunitinib were 3 and 7 patients with metastatic breast cancer ulcer, and the median time to progression （TTP） was 2. 0 months. The most common adverse events included fatigue, hand-foot syndrome, neutropenia, thrombocytopenia and hypertension. Conclusion Single-agent sunitinib treatment of refractory advanced breast cancer ulcer has marked efficacies. However, neutropenia, thrombocytopenia and hypertension are the major dose-limited toxicities.